Leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:37:26 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-venetoclax-with-fludarabine-amsacrine-and-cytarabine-for-patients-with-mds-cmml-or-secondary-aml-undergoing-stem-cell-transplantation/ Wed, 29 Apr 2026 15:01:26 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-venetoclax-with-fludarabine-amsacrine-and-cytarabine-for-patients-with-mds-cmml-or-secondary-aml-undergoing-stem-cell-transplantation/ This clinical trial is focused on evaluating the safety and effectiveness of a treatment plan for patients with certain types of blood disorders, specifically Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), and Secondary Acute Myeloid Leukemia (sAML). The treatment involves the use of a medication called Venetoclax, which is taken orally in the form of a film-coated tablet. Venetoclax is being tested in combination with a series of other medications, including Fludarabine, Amsacrine, Ara-C (also known as Cytarabine), and Treosulfan, as part of a conditioning regimen before a procedure known as allogeneic blood stem cell transplantation.

The purpose of the study is to determine if adding Venetoclax to this treatment regimen is safe for patients undergoing the transplantation procedure. The study will follow participants through the course of their treatment, which includes taking the medications and undergoing the transplantation. The medications are administered in different ways: Venetoclax is taken orally, while Amsacrine and Cytarabine are given intravenously. The study will monitor the patients’ health and any side effects they may experience during and after the treatment.

Participants in the study will be observed for a period of time after the transplantation to assess the safety of the treatment, including any potential organ toxicity and other adverse effects. The study will also look at how well the treatment works in terms of disease response and overall survival. This research aims to improve the outcomes for patients with high-risk forms of MDS, CMML, and sAML by finding the most effective and safe treatment combinations.

]]> Study on the Safety of ATreg Cells for Patients with Leukemia After Stem Cell Transplant to Reduce Graft vs Host Disease https://clinicaltrials.eu/trial/study-on-the-safety-of-atreg-cells-for-patients-with-leukemia-after-stem-cell-transplant-to-reduce-graft-vs-host-disease/ Wed, 29 Apr 2026 14:58:45 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-atreg-cells-for-patients-with-leukemia-after-stem-cell-transplant-to-reduce-graft-vs-host-disease/ This clinical trial is focused on studying the safety and tolerability of a new treatment for patients who have undergone a haematopoietic stem cell transplantation (HSCT). The treatment involves using a special type of immune cell called GP120-activated regulatory T cells (ATreg). These cells are designed to help reduce the incidence and severity of a condition known as acute Graft vs Host Disease (GvHD), which can occur after a stem cell transplant. The study is particularly relevant for patients with blood cancers such as leukaemia, who require a stem cell transplant as part of their treatment.

The purpose of the study is to assess how safe and tolerable the ATreg treatment is for patients. Participants in the study will receive the ATreg treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants for any serious side effects related to the treatment at various intervals, including 24 hours, 3 days, 7 days, and 14 days after receiving the ATreg infusion. Additionally, the study will observe the effects of the treatment on the incidence and severity of acute GvHD, as well as any potential infections or relapses of the underlying blood cancer.

Throughout the study, researchers will also track changes in blood components such as neutrophils, platelets, and haemoglobin to assess how well the transplanted cells are taking hold in the body. The study will continue to monitor participants for up to six months after the ATreg treatment to gather comprehensive data on the treatment’s long-term effects, including any occurrences of GvHD, infections, or cancer relapse. This trial aims to provide valuable insights into the potential benefits and risks of using ATreg cells in patients who have recently undergone a stem cell transplant.

]]> Study of dasatinib treatment in children and adolescents with Philadelphia chromosome-positive leukemia who cannot take imatinib or for whom imatinib is not effective https://clinicaltrials.eu/trial/study-of-dasatinib-for-children-and-adolescents-with-chronic-myeloid-leukemia-or-ph-leukemias-resistant-or-intolerant-to-imatinib/ Wed, 29 Apr 2026 14:29:44 +0000 https://clinicaltrials.eu/trial/study-of-dasatinib-for-children-and-adolescents-with-chronic-myeloid-leukemia-or-ph-leukemias-resistant-or-intolerant-to-imatinib/ This study focuses on treating children and adolescents with Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+) leukemias who either have newly diagnosed disease or have not responded well to treatment with imatinib. The study will test a medication called dasatinib (also known as Sprycel), which is available as both tablets and as a powder that can be made into a liquid for drinking.

The main purpose is to determine how well dasatinib works in young patients whose leukemia has either become resistant to imatinib treatment or who cannot tolerate imatinib’s side effects. The study will also look at how dasatinib works in patients who have just been diagnosed with CML. Resistance means the cancer continues to grow despite treatment, while intolerance means experiencing severe side effects that prevent continuing the medication.

During the study, participants will receive dasatinib treatment, and doctors will monitor how their disease responds to the medication. The study will track several important measures of treatment success, including how well the medication controls blood cell counts and whether it reduces or eliminates cancer cells that contain the Philadelphia chromosome, a specific genetic change found in these types of leukemia.

]]> Hematoonkologia https://clinicaltrials.eu/organisation/hematoonkologia/ Wed, 29 Apr 2026 13:34:18 +0000 https://clinicaltrials.eu/organisation/hematoonkologia/ Fundacja Hematoonkologia is a Polish non-profit organization that serves as a key source of support and information for patients with hematological cancers. The foundation offers accessible materials on diagnosis, treatment methods, symptoms, and living with hematological diseases (e.g., leukemias, lymphomas, multiple myeloma). It also helps families cope with emotional challenges. The foundation works to raise public awareness about hematological cancers.

]]>